VBL Therapeutics to Present at Upcoming Conferences

Rhea-AI Summary

TEL AVIV, Israel, Sept. 10, 2021 – VBL Therapeutics (NASDAQ: VBLT) has announced its participation in several upcoming industry conferences. The H.C. Wainwright 23rd Annual Global Investment Conference is set for September 13, 2021, with an on-demand fireside chat at 7:00 a.m. ET. VBL will also present at the Cell & Gene Therapy World Asia 2021 conference on September 15, focusing on their gene therapy product VB-111. Lastly, the company will join the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22. Webcasts will be available on the company’s Investor Relations page.

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences:

H.C. Wainwright 23rd Annual Global Investment Conference
Mon., Sept. 13, 2021
Fireside chat available on-demand beginning at 7:00 a.m. ET

Cell & Gene Therapy World Asia 2021 conference
Wed., Sept. 15, 2021
Presentation Time: 4:45 PM (SGT)
Keynote Presentation Topic: VB-111: Transformative Gene therapy with the Potential to Change the Treatment Paradigm for Solid Tumors

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Wed., Sept. 22, 2021
Fireside chat at 1:15 PM - 1:55 PM (ET).

Webcasts will be available via the Events and Presentations section of the Company’s Investor Relations page.

About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer and immune or inflammatory indications. VBL has developed three platform technologies: a gene-therapy based platform for targeting newly formed blood vessels with focus on cancer, an antibody-based platform targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the lecinoxoids platform, comprised of a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 registration-enabling trial for platinum-resistant ovarian cancer. To learn more about VBL Therapeutics, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

CONTACT:
Catherine Day
+1-917-763-2709
Catherine@newdaybioconsulting.com

FAQ

What are the upcoming conferences VBL Therapeutics will participate in?

VBL Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, the Cell & Gene Therapy World Asia 2021 conference on September 15, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021.

When is VBL Therapeutics' keynote presentation at the Cell & Gene Therapy World Asia 2021?

VBL Therapeutics' keynote presentation at the Cell & Gene Therapy World Asia 2021 is scheduled for September 15, 2021, at 4:45 PM (SGT).

What is the focus of VBL Therapeutics' presentation at the Cell & Gene Therapy World Asia 2021?

The focus of VBL Therapeutics' presentation at the Cell & Gene Therapy World Asia 2021 is on VB-111, a transformative gene therapy with the potential to change the treatment paradigm for solid tumors.

What time will VBL Therapeutics participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit?

VBL Therapeutics will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit with a fireside chat scheduled from 1:15 PM to 1:55 PM (ET) on September 22, 2021.

How can I access VBL Therapeutics' webcasts from the conferences?

Webcasts from VBL Therapeutics' conferences will be available via the Events and Presentations section of the company's Investor Relations page.